Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
The fastest path to regulatory-grade AI is rarely the one that starts from scratch — and rarely the one that hands over control. Here is how mature pharma organizations are doing both.
Regulatory-grade AI refers to AI systems designed for regulated life sciences environments, where outputs must be accurate, traceable, repeatable, and compliant with regulatory expectations such as GxP, auditability, and data integrity.
Every delay in the regulatory submission process has downstream consequences, slowing the path between scientific progress and patient access. That is the real backdrop to the question every life sciences leadership team is now asking: do we build our AI capabilities in-house, or buy from a specialized vendor?
The debate is usually framed as a binary — control versus speed, IP versus dependency, internal expertise versus external innovation. In practice, that framing is the problem. The organizations getting the most value from AI in regulated environments today have stopped treating build and buy as opposing strategies. They are doing both, deliberately, and with a clear view of where each approach actually creates value.
The most effective approach for pharma organizations is rarely purely build or purely buy. Mature organizations build where they create strategic differentiation and buy where they need scalable, regulatory-grade infrastructure and domain expertise.
There are legitimate reasons to build. A capability that is genuinely differentiating — something tied to proprietary data, a unique scientific approach, or a workflow no one else has solved — deserves internal investment. That is where IP strategy belongs.
But the cost of building regulatory-grade AI is consistently underestimated.
Cost. One top-10 pharmaceutical company recently estimated that automating Clinical Study Report generation alone would require an internal investment of five to ten million dollars — and that covered only the first version of the platform.
Maintenance. The initial build is only the beginning. Teams must continuously maintain prompts, pipelines, integrations, validation frameworks, and structured authoring environments while adapting to new document types and evolving business needs.
Governance. In regulated environments, AI systems must support GxP validation, audit trails, change control, security reviews, traceability, and controlled review workflows. These requirements add operational complexity that is often underestimated at kickoff.
Model evolution. Frontier models evolve every few months. Keeping pace requires ongoing evaluation, testing, and optimization to ensure outputs remain reliable, compliant, and operationally relevant as both regulations and model capabilities change.
By year two or three, the team that was supposed to be advancing the platform is spending most of its time keeping it alive. The capability is real, but so is the opportunity cost.
Most internal AI projects in life sciences do not fail at launch. They fail eighteen months later, when maintenance, governance, validation, and evolving model requirements overwhelm the original roadmap.
Pharma IT and data science teams are exceptionally strong. That is not the question. The question is whether technical strength translates into the regulatory and scientific judgment needed to prioritize the right features at the right time.
Specialized vendors live inside these workflows every day. They understand the structure of a CSR, the implications of ICH M11 and ICH M4Q(R2), the difference between a preclinical study report and a Module 2.4 summary, the cadence of health authority feedback, and the kinds of traceability auditors expect when generative AI sits anywhere near a regulatory submission.
That depth shows up in product decisions that are difficult to replicate from the outside: which document sections require deterministic generation versus LLM-assisted drafting, where symbolic logic prevents hallucination, how reviewers want to see citations surfaced, what explainability actually means to a regulator. These are not engineering problems. They are domain problems, and they take years of dedicated focus to solve well.
Yseop has spent that time. The Yseop Copilot platform is in production at GSK, Sanofi, Novartis, Lilly, PPD, and Pierre Fabre, has supported more than 300 clinical trials, and has been used in submissions approved by both the FDA and EMA. In a recent GSK production study, Yseop delivered a 70 percent reduction in CTN authoring time — 1,276 hours saved across twelve CTNs in a single year — with fewer than seven percent of generated sections requiring re-authoring. That is the kind of operational signal that takes a decade of domain focus to produce.
There is a second, less discussed cost of building: time. A multi-year internal program assumes that the requirements at kickoff will still be the requirements at launch. In AI for life sciences, that assumption no longer holds.
Regulatory expectations are evolving — AI governance frameworks, transparency requirements, and structured content standards are being rewritten in real time. Model capabilities are evolving even faster. The architecture that looked optimal in 2024 is already legacy in 2026. And business needs shift as therapeutic pipelines, partnerships, and submission strategies change.
By the time an internal solution reaches maturity, the organization is often solving last year’s problem with last year’s tools. A specialized vendor, by contrast, is amortizing R&D across an entire customer base and absorbing each shift as part of its core mandate.
Most generative AI tools were not built for regulated environments, and it shows: Content generation is easy. Accuracy, traceability, and repeatability are not. The gap between a model that can draft a plausible paragraph and a system that can produce content fit to submit to a regulator is not a tuning problem — it is an architectural one.
Yseop is built on a neuro-symbolic agentic AI architecture. Large language models bring generative flexibility; a symbolic control layer enforces rules, validates against regulatory standards, and maintains traceability from source data to sentence. Agents orchestrate drafting, validation, and review across teams. Humans remain in the loop where it matters. Agents execute, humans decide.
That architecture is what makes regulatory-grade AI possible — and it rests on three principles that any serious life sciences buyer should hold a platform to:
These are not features. They are architectural commitments that take years to build and validate, and they are precisely the commitments that internal programs tend to underestimate at kickoff.
Recent FDA actions reinforce why these requirements matter. In 2026, the agency issued a warning letter highlighting risks associated with AI use in drug manufacturing, including concerns around validation, oversight, and reliability of automated systems. The signal is broader than manufacturing alone: regulators are beginning to distinguish between AI that is operationally impressive and AI that is sufficiently governed for regulated use.
The build-versus-buy debate dissolves once leaders separate two questions that are usually conflated. Where does this capability create genuine competitive differentiation for us? Build, and protect the IP. Where do we need a regulatory-grade, validated, continuously improving foundation? Buy, and integrate it into the workflows we own.
This is, in practice, how the most mature pharma adopters are operating. They keep strategic control of the parts that matter — their data, their governance standards, their scientific judgment, their integration with their authoring ecosystem — while letting a specialized partner carry the burden of maintaining and evolving the underlying platform. The result is faster adoption, lower long-term maintenance, and a platform that keeps getting better without consuming the team that built it.
It is where to spend internal effort so that it compounds, and where to lean on external expertise so that it scales. In regulated AI, the cost of getting that allocation wrong is measured in years of delay and millions in sunk effort. The cost of getting it right is measured in something more important: treatments that reach patients sooner.
Regulatory-grade AI refers to AI systems designed for regulated life sciences environments where outputs must be accurate, traceable, repeatable, and compliant with regulatory expectations.
Most mature pharma organizations combine both approaches: building capabilities that create strategic differentiation while buying proven infrastructure and domain-specific platforms.
Building AI internally requires ongoing investment in validation, governance, infrastructure, compliance, model maintenance, and domain expertise, which are often underestimated.
Regulatory AI systems must reflect regulatory expectations, document structures, auditability requirements, and submission workflows that require deep life sciences expertise.
AI systems for regulated environments must provide accurate outputs, full traceability, repeatable performance, governed workflows, and human oversight.